Proprotein convertase subtilisin/kexin type 9 (PCSK9) single domain antibodies are potent inhibitors of low density lipoprotein receptor degradation

Journal of Biological Chemistry

Volumn 291, Issue 32, 2016, Pages 16659-16671

  Weider, Elodie ^a   Susan Resiga, Delia ^a   Essalmani, Rachid ^a   Hamelin, Josée ^a   Asselin, Marie Claude ^a   Nimesh, Surendra ^a   Ashraf, Yahya ^a   Wycoff, Keith L ^b   Zhang, Jianbing ^c,d   Prat, Annik ^a   Seidah, Nabil G ^a  

^a CLIN RESEARCH INSTITUTE OF MONTREAL   (Canada)

^b Planet Biotechnology Inc   (United States)

^c NATIONAL RESEARCH COUNCIL CANADA   (Canada)

^d Xiangxue Pharma ^*  (China)

Author keywords

[No Author keywords available]

Indexed keywords

ANTIGENS; BINDING ENERGY; BINS; CELL CULTURE; CHOLESTEROL; LIPOPROTEINS; MAMMALS; MONOCLONAL ANTIBODIES; PROTEINS;

BACTERIAL ARTIFICIAL CHROMOSOMES; HUMAN HEPATOCYTES; LOW DENSITY LIPOPROTEIN RECEPTORS; MONOCLONAL ANTIBODIES (MABS); PRIMARY HEPATOCYTES; PROOF OF PRINCIPLES; SINGLE-DOMAIN ANTIBODIES; TOTAL CHOLESTEROLS;

ANTIBODIES;

APOLIPOPROTEIN B; CYSTINE; FC RECEPTOR; HISTIDINE; KEXIN; LOW DENSITY LIPOPROTEIN CHOLESTEROL; LOW DENSITY LIPOPROTEIN RECEPTOR; NANOBODY; PROTEIN PCSK9; UNCLASSIFIED DRUG; LDLR PROTEIN, HUMAN; PCSK9 PROTEIN, HUMAN; PCSK9 PROTEIN, MOUSE; PROPROTEIN CONVERTASE 9;

ANIMAL CELL; ANIMAL EXPERIMENT; ANTIBODY ISOLATION; ANTIGEN ANTIBODY COMPLEX; ANTIGEN BINDING; ANTIGEN RECOGNITION; ARTICLE; BACTERIAL ARTIFICIAL CHROMOSOME; BINDING AFFINITY; CARBOXY TERMINAL SEQUENCE; CELL ASSAY; CHOLESTEROL BLOOD LEVEL; CONTROLLED STUDY; HUMAN; HUMAN CELL; IMMUNIZATION; LIVER CELL; LLAMA; MALE; MOUSE; NONHUMAN; PRIORITY JOURNAL; PROMOTER REGION; PROTEIN BLOOD LEVEL; PROTEIN DEGRADATION; PROTEIN DOMAIN; PROTEIN EXPRESSION; TRANSGENE; ANIMAL; ANTAGONISTS AND INHIBITORS; DRUG EFFECTS; GENETICS; HEK293 CELL LINE; KNOCKOUT MOUSE; METABOLISM;

ANIMALS; CHOLESTEROL, LDL; HEK293 CELLS; HUMANS; MICE; MICE, KNOCKOUT; PROPROTEIN CONVERTASE 9; PROTEOLYSIS; RECEPTORS, LDL; SINGLE-DOMAIN ANTIBODIES;

EID: 84982868501     PISSN: 00219258     EISSN: 1083351X     Source Type: Journal    
DOI: 10.1074/jbc.M116.717736     Document Type: Article

References (73)

1. Cholesterol Treatment Trialists' (CTT) Collaboration, Baigent, C., Blackwell, L., Emberson, J., Holland, L. E., Reith, C., Bhala, N., Peto, R., Barnes, E. H., Keech, A., Simes, J., and Collins, R. (2010) Efficacy and safety of more intensive lowering of LDL cholesterol: a meta-analysis of data from 170,000 participants in 26 randomised trials. Lancet 376, 1670-1681
2. Hobbs, H. H., Brown, M. S., and Goldstein, J. L. (1992) Molecular genetics of the LDL receptor gene in familial hypercholesterolemia. Hum. Mutat. 1, 445-466
3. Seidah, N. G., Benjannet, S., Wickham, L., Marcinkiewicz, J., Jasmin, S. B., Stifani, S., Basak, A., Prat, A., and Chretien, M. (2003) The secretory proprotein convertase neural apoptosis-regulated convertase 1 (NARC-1): liver regeneration and neuronal differentiation. Proc. Natl. Acad. Sci. U.S.A. 100, 928-933
4. Abifadel, M., Varret, M., Rabs, J. P., Allard, D., Ouguerram, K., Devillers, M., Cruaud, C., Benjannet, S., Wickham, L., Erlich, D., Derré, A., Villéger, L., Farnier, M., Beucler, I., Bruckert, E., Chambaz, J., Chanu, B., Lecerf, J. M., Luc, G., Moulin, P., Weissenbach, J., Prat, A., Krempf, M., Junien, C., Seidah, N. G., and Boileau, C. (2003) Mutations in PCSK9 cause autosomal dominant hypercholesterolemia. Nat. Genet. 34, 154-156
5. Seidah, N. G., and Prat, A. (2012) The biology and therapeutic targeting of the proprotein convertases. Nat. Rev. Drug. Discov. 11, 367-383
6. Cunningham, D., Danley, D. E., Geoghegan, K. F., Griffor, M. C., Hawkins, J. L., Subashi, T. A., Varghese, A. H., Ammirati, M. J., Culp, J. S., Hoth, L. R., Mansour, M. N., McGrath, K. M., Seddon, A. P., Shenolikar, S., Stutzman-Engwall, K. J., et al. (2007) Structural and biophysical studies of PCSK9 and its mutants linked to familial hypercholesterolemia. Nat. Struct. Mol. Biol. 14, 413-419
7. Nassoury, N., Blasiole, D. A., Tebon Oler, A., Benjannet, S., Hamelin, J., Poupon, V., McPherson, P. S., Attie, A. D., Prat, A., and Seidah, N. G. (2007) The cellular trafficking of the secretory proprotein convertase PCSK9 and its dependence on the LDLR. Traffic 8, 718-732
8. Zhang, D. W., Lagace, T. A., Garuti, R., Zhao, Z., McDonald, M., Horton, J. D., Cohen, J. C., and Hobbs, H. H. (2007) Binding of proprotein convertase subtilisin/kexin type 9 to epidermal growth factor-like repeat a of low density lipoprotein receptor decreases receptor recycling and increases degradation. J. Biol. Chem. 282, 18602-18612
9. Maxwell, K. N., and Breslow, J. L. (2004) Adenoviral-mediated expression of Pcsk9 in mice results in a low-density lipoprotein receptor knockout phenotype. Proc. Natl. Acad. Sci. U.S.A. 101, 7100-7105
10. Benjannet, S., Rhainds, D., Essalmani, R., Mayne, J., Wickham, L., Jin, W., Asselin, M. C., Hamelin, J., Varret, M., Allard, D., Trillard, M., Abifadel, M., Tebon, A., Attie, A. D., Rader, D. J., et al. (2004) NARC-1/PCSK9 and its natural mutants: zymogen cleavage and effects on the low density lipoprotein (LDL) receptor and LDL cholesterol. J. Biol. Chem. 279, 48865-48875
11. Park, S. W., Moon, Y. A., and Horton, J. D. (2004) Post-transcriptional regulation of low density lipoprotein receptor protein by proprotein convertase subtilisin/kexin type 9a in mouse liver. J. Biol. Chem. 279, 50630-50638
12. Lo Surdo, P., Bottomley, M. J., Calzetta, A., Settembre, E. C., Cirillo, A., Pandit, S., Ni, Y. G., Hubbard, B., Sitlani, A., and Carfí, A. (2011) Mechanistic implications for LDL receptor degradation from the PCSK9/LDLR structure at neutral pH. EMBO Rep. 12, 1300-1305
13. Poirier, S., Mayer, G., Benjannet, S., Bergeron, E., Marcinkiewicz, J., Nassoury, N., Mayer, H., Nimpf, J., Prat, A., and Seidah, N. G. (2008) The proprotein convertase PCSK9 induces the degradation of low density lipoprotein receptor (LDLR) and its closest family members VLDLR and ApoER2. J. Biol. Chem. 283, 2363-2372
14. Shan, L., Pang, L., Zhang, R., Murgolo, N. J., Lan, H., and Hedrick, J. A. (2008) PCSK9 binds to multiple receptors and can be functionally inhibited by an EGF-A peptide. Biochem. Biophys. Res. Commun. 375, 69-73
15. Canuel, M., Sun, X., Asselin, M.-C., Paramithiotis, E., Prat, A., and Seidah, N. G. (2013) Proprotein convertase subtilisin/kexin type 9 (PCSK9) can mediate degradation of the low density lipoprotein receptor-related protein 1 (LRP-1). PLoS ONE 8, e64145
16. Huang, S., Henry, L., Ho, Y. K., Pownall, H. J., and Rudenko, G. (2010) Mechanism of LDL binding and release probed by structure-based mutagenesis of the LDL receptor. J. Lipid Res. 51, 297-308
17. Holla, Ø. L., Cameron, J., Berge, K. E., Ranheim, T., and Leren, T. P. (2007) Degradation of the LDL receptors by PCSK9 is not mediated by a secreted protein acted upon by PCSK9 extracellularly. BMC Cell Biol. 8, 9-20
18. Zhang, D. W., Garuti, R., Tang, W. J., Cohen, J. C., and Hobbs, H. H. (2008) Structural requirements for PCSK9-mediated degradation of the low-density lipoprotein receptor. Proc. Natl. Acad. Sci. U.S.A. 105, 13045-13050
19. Timms, K. M., Wagner, S., Samuels, M. E., Forbey, K., Goldfine, H., Jammulapati, S., Skolnick, M. H., Hopkins, P. N., Hunt, S. C., and Shattuck, D. M. (2004) A mutation in PCSK9 causing autosomal-dominant hypercholesterolemia in a Utah pedigree. Hum. Genet. 114, 349-353
20. Cohen, J., Pertsemlidis, A., Kotowski, I. K., Graham, R., Garcia, C. K., and Hobbs, H. H. (2005) Low LDL cholesterol in individuals of African descent resulting from frequent nonsense mutations in PCSK9. Nat. Genet. 37, 161-165
21. Kotowski, I. K., Pertsemlidis, A., Luke, A., Cooper, R. S., Vega, G. L., Cohen, J. C., and Hobbs, H. H. (2006) A spectrum of PCSK9 alleles contributes to plasma levels of low-density lipoprotein cholesterol. Am. J. Hum. Genet. 78, 410-422
22. Seidah, N. G., Awan, Z., Chrétien, M., and Mbikay, M. (2014) PCSK9: a key modulator of cardiovascular health. Circ. Res. 114, 1022-1036
23. Seidah, N. G. (2009) PCSK9 as a therapeutic target of dyslipidemia. Expert Opin. Therapeutic Targets 13, 19-28
24. Stein, E. A., and Raal, F. (2014) Reduction of low-density lipoprotein cholesterol by monoclonal antibody inhibition of PCSK9. Annu. Rev. Med. 65, 417-431
25. McLaughlin, P., Grillo-López, A. J., Link, B. K., Levy, R., Czuczman, M. S., Williams, M. E., Heyman, M. R., Bence-Bruckler, I., White, C. A., Cabanillas, F., Jain, V., Ho, A. D., Lister, J., Wey, K., Shen, D., and Dallaire, B. K. (1998) Rituximab chimeric anti-CD20 monoclonal antibody therapy for relapsed indolent lymphoma: half of patients respond to a four-dose treatment program. J. Clin. Oncol. 16, 2825-2833
26. Lundin, J., Kimby, E., Björkholm, M., Broliden, P. A., Celsing, F., Hjalmar, V., Möllgård, L., Rebello, P., Hale, G., Waldmann, H., Mellstedt, H., and Osterborg, A. (2002) Phase II trial of subcutaneous anti-CD52 monoclonal antibody alemtuzumab (Campath-1H) as first-line treatment for patients with B-cell chronic lymphocytic leukemia (B-CLL). Blood 100, 768-773
27. Cobleigh, M. A., Vogel, C. L., Tripathy, D., Robert, N. J., Scholl, S., Fehrenbacher, L., Wolter, J. M., Paton, V., Shak, S., Lieberman, G., and Slamon, D. J. (1999) Multinational study of the efficacy and safety of humanized anti-HER2 monoclonal antibody in women who have HER2-overexpressing metastatic breast cancer that has progressed after chemotherapy for metastatic disease. J. Clin. Oncol. 17, 2639-2648
28. Shrank, W. H., Barlow, J. F., and Brennan, T. A. (2015) New therapies in the treatment of high cholesterol: an argument to return to goal-based lipid guidelines. JAMA 314, 1443-1444
29. Genest, J., McPherson, R., Frohlich, J., Anderson, T., Campbell, N., Carpentier, A., Couture, P., Dufour, R., Fodor, G., Francis, G. A., Grover, S., Gupta, M., Hegele, R. A., Lau, D. C., Leiter, L., et al. (2009) 2009 Canadian Cardiovascular Society/Canadian guidelines for the diagnosis and treatment of dyslipidemia and prevention of cardiovascular disease in the adult- 2009 recommendations. Can. J. Cardiol. 25, 567-579
30. Hamers-Casterman, C., Atarhouch, T., Muyldermans, S., Robinson, G., Hamers, C., Songa, E. B., Bendahman, N., and Hamers, R. (1993) Naturally occurring antibodies devoid of light chains. Nature 363, 446-448
31. Muyldermans, S. (2013) Nanobodies: natural single-domain antibodies. Annu. Rev. Biochem. 82, 775-797
32. van der Linden, R., de Geus, B., Stok, W., Bos, W., van Wassenaar, D., Verrips, T., and Frenken, L. (2000) Induction of immune responses and molecular cloning of the heavy chain antibody repertoire of Lama glama. J. Immunol. Methods 240, 185-195
33. Vincke, C., Loris, R., Saerens, D., Martinez-Rodriguez, S., Muyldermans, S., and Conrath, K. (2009) General strategy to humanize a camelid single-domain antibody and identification of a universal humanized nanobody scaffold. J. Biol. Chem. 284, 3273-3284
34. Bartunek, J., Barbato, E., Heyndrickx, G., Vanderheyden, M., Wijns, W., and Holz, J. B. (2013) Novel antiplatelet agents: ALX-0081, a Nanobody directed towards von Willebrand factor. J. Cardiovasc Transl Res. 6, 355-363
35. Kratz, F., and Elsadek, B. (2012) Clinical impact of serum proteins on drug delivery. J. Control Release 161, 429-445
36. Sarker, S. A., Jäkel, M., Sultana, S., Alam, N. H., Bardhan, P. K., Chisti, M. J., Salam, M. A., Theis, W., Hammarström, L., and Frenken, L. G. (2013) Anti-rotavirus protein reduces stool output in infants with diarrhea: a randomized placebo-controlled trial. Gastroenterology 145, 740-748
37. Saavedra, Y. G., Day, R., and Seidah, N. G. (2012) The M2 module of the Cys-His-rich domain (CHRD) of PCSK9 is needed for the extracellular low density lipoprotein receptor (LDLR) degradation pathway. J. Biol. Chem. 287, 43492-43501
38. Powers, D. B., Amersdorfer, P., Poul, M., Nielsen, U. B., Shalaby, M. R., Adams, G. P., Weiner, L. M., and Marks, J. D. (2001) Expression of single-chain Fv-Fc fusions in Pichia pastoris. J. Immunol. Methods 251, 123-135
39. Zaid, A., Roubtsova, A., Essalmani, R., Marcinkiewicz, J., Chamberland, A., Hamelin, J., Tremblay, M., Jacques, H., Jin, W., Davignon, J., Seidah, N. G., and Prat, A. (2008) Proprotein convertase subtilisin/kexin type 9 (PCSK9): Hepatocyte-specific low-density lipoprotein receptor degradation and critical role in mouse liver regeneration. Hepatology 48, 646-654
40. Essalmani, R., Susan-Resiga, D., Chamberland, A., Abifadel, M., Creemers, J. W., Boileau, C., Seidah, N. G., and Prat, A. (2011) In vivo evidence that furin from hepatocytes inactivates PCSK9. J. Biol. Chem. 286, 4257-4263
41. Ly, K., Saavedra, Y. G., Canuel, M., Routhier, S., Desjardins, R., Hamelin, J., Mayne, J., Lazure, C., Seidah, N. G., and Day, R. (2014) Annexin A2 reduces PCSK9 protein levels via a translational mechanism and interacts with the M1 and M2 domains of PCSK9. J. Biol. Chem. 289, 17732-17746
42. Benjannet, S., Hamelin, J., Chrétien, M., and Seidah, N. G. (2012) Loss- and gain-of-function PCSK9 variants: cleavage specificity, dominant negative effects, and low density lipoprotein receptor (LDLR) degradation. J. Biol. Chem. 287, 33745-33755
43. Pedersen, N. B., Wang, S., Narimatsu, Y., Yang, Z., Halim, A., Schjoldager, K. T., Madsen, T. D., Seidah, N. G., Bennett, E. P., Levery, S. B., and Clausen, H. (2014) Low density lipoprotein receptor class A repeats are O-glycosylated in linker regions. J. Biol. Chem. 289, 17312-17324
44. Pelham, H. R. (1988) Evidence that luminal ER proteins are sorted from secreted proteins in a post-ER compartment. EMBO J. 7, 913-918
45. Poirier, S., Mamarbachi, M., Chen, W. T., Lee, A. S., and Mayer, G. (2015) GRP94 Regulates circulating cholesterol levels through blockade of PCSK9-induced LDLR degradation. Cell Rep. 13, 2064-2071
46. Poirier, S., Mayer, G., Poupon, V., McPherson, P. S., Desjardins, R., Ly, K., Asselin, M. C., Day, R., Duclos, F. J., Witmer, M., Parker, R., Prat, A., and Seidah, N. G. (2009) Dissection of the endogenous cellular pathways of PCSK9-induced LDLR degradation: evidence for an intracellular route. J. Biol. Chem. 284, 28856-28864
47. Roubtsova, A., Munkonda, M. N., Awan, Z., Marcinkiewicz, J., Chamberland, A., Lazure, C., Cianflone, K., Seidah, N. G., and Prat, A. (2011) Circulating proprotein convertase subtilisin/kexin 9 (PCSK9) regulates VLDLR protein and triglyceride accumulation in visceral adipose tissue. Arterioscler. Thromb. Vasc. Biol. 31, 785-791
48. Roubtsova, A., Chamberland, A., Marcinkiewicz, J., Essalmani, R., Fazel, A., Bergeron, J. J., Seidah, N. G., and Prat, A. (2015) PCSK9 deficiency unmasks a sex/tissue-specific subcellular distribution of the LDL and VLDL receptors in mice. J. Lipid Res. 56, 2133-2142
49. Chan, J. C., Piper, D. E., Cao, Q., Liu, D., King, C., Wang, W., Tang, J., Liu, Q., Higbee, J., Xia, Z., Di, Y., Shetterly, S., Arimura, Z., Salomonis, H., Romanow, W. G., et al. (2009) A proprotein convertase subtilisin/kexin type 9 neutralizing antibody reduces serum cholesterol in mice and non-human primates. Proc. Natl. Acad. Sci. U.S.A. 106, 9820-9825
50. Marcinkiewicz, M., Ramla, D., Seidah, N. G., and Chrétien, M. (1994) Developmental expression of the prohormone convertases PC1 and PC2 in mouse pancreatic islets. Endocrinology 135, 1651-1660
51. Ni, Y. G., Condra, J. H., Orsatti, L., Shen, X., Di Marco, S., Pandit, S., Bottomley, M. J., Ruggeri, L., Cummings, R. T., Cubbon, R. M., Santoro, J. C., Ehrhardt, A., Lewis, D., Fisher, T. S., Ha, S., et al. (2010) A proprotein convertase subtilisin-like/kexin type 9 (PCSK9) C-terminal domain antibody antigen-binding fragment inhibits PCSK9 internalization and restores low density lipoprotein uptake. J. Biol. Chem. 285, 12882-12891
52. Schiele, F., Park, J., Redemann, N., Luippold, G., and Nar, H. (2014) An antibody against the C-terminal domain of PCSK9 lowers LDL cholesterol levels in vivo. J. Mol. Biol. 426, 843-852
53. Butkinaree, C., Canuel, M., Essalmani, R., Poirier, S., Benjannet, S., Asselin, M.-C., Roubtsova, A., Hamelin, J., Marcinkiewicz, J., Chamberland, A., Guillemot, J., Mayer, G., Sisodia, S. S., Jacob, Y., Prat, A., and Seidah, N. G. (2015) Amyloid precursor-like protein 2 and sortilin do not regulate the PCSK9-mediated low density lipoprotein receptor degradation but interact with each other. J. Biol. Chem. 290, 18609-18620
54. Zhang, Y., Zhou, L., Kong-Beltran, M., Li, W., Moran, P., Wang, J., Quan, C., Tom, J., Kolumam, G., Elliott, J. M., Skelton, N. J., Peterson, A. S., and Kirchhofer, D. (2012) Calcium-independent inhibition of PCSK9 by affinity-improved variants of the LDL receptor EGF(A) domain. J. Mol. Biol. 422, 685-696
55. Ni, Y. G., Di Marco, S., Condra, J. H., Peterson, L. B., Wang, W., Wang, F., Pandit, S., Hammond, H. A., Rosa, R., Cummings, R. T., Wood, D. D., Liu, X., Bottomley, M. J., Shen, X., Cubbon, R. M., et al. (2011) A PCSK9-binding antibody that structurally mimics the EGF(A) domain of LDLreceptor reduces LDL cholesterol in vivo. J. Lipid Res. 52, 78-86
56. Mitchell, T., Chao, G., Sitkoff, D., Lo, F., Monshizadegan, H., Meyers, D., Low, S., Russo, K., DiBella, R., Denhez, F., Gao, M., Myers, J., Duke, G., Witmer, M., Miao, B., et al. (2014) Pharmacologic profile of the adnectin BMS-962476, a small protein biologic alternative to PCSK9 antibodies for low-density lipoprotein lowering. J. Pharmacol. Exp. Ther. 350, 412-424
57. Graham, M. J., Lemonidis, K. M., Whipple, C. P., Subramaniam, A., Monia, B. P., Crooke, S. T., and Crooke, R. M. (2007) Antisense inhibition of proprotein convertase subtilisin/kexin type 9 reduces serum LDL in hyperlipidemic mice. J. Lipid Res. 48, 763-767
58. Gupta, N., Fisker, N., Asselin, M. C., Lindholm, M., Rosenbohm, C., Ørum, H., Elmén, J., Seidah, N. G., and Straarup, E. M. (2010) A locked nucleic acid antisense oligonucleotide (LNA) silences PCSK9 and enhances LDLR expression in vitro and in vivo. PLoS ONE 5, e10682
59. Yamamoto, T., Harada-Shiba, M., Nakatani, M., Wada, S., Yasuhara, H., Narukawa, K., Sasaki, K., Shibata, M. A., Torigoe, H., Yamaoka, T., Imanishi, T., and Obika, S. (2012) Cholesterol-lowering action of BNA-based antisense oligonucleotides targeting PCSK9 in atherogenic diet-induced hypercholesterolemic mice. Mol. Ther. Nucleic Acids 1, e22
60. Frank-Kamenetsky, M., Grefhorst, A., Anderson, N. N., Racie, T. S., Bramlage, B., Akinc, A., Butler, D., Charisse, K., Dorkin, R., Fan, Y., Gamba-Vitalo, C., Hadwiger, P., Jayaraman, M., John, M., Jayaprakash, K. N., et al. (2008) Therapeutic RNAi targeting PCSK9 acutely lowers plasma cholesterol in rodents and LDL cholesterol in nonhuman primates. Proc. Natl. Acad. Sci. U.S.A. 105, 11915-11920
61. Galabova, G., Brunner, S., Winsauer, G., Juno, C., Wanko, B., Mairhofer, A., Lührs, P., Schneeberger, A., von Bonin, A., Mattner, F., Schmidt, W., and Staffler, G. (2014) Peptide-based anti-PCSK9 vaccines- an approach for long-term LDLc management. PLoS ONE 9, e114469
62. Crossey, E., Amar, M. J., Sampson, M., Peabody, J., Schiller, J. T., Chackerian, B., and Remaley, A. T. (2015) A cholesterol-lowering VLP vaccine that targets PCSK9. Vaccine 33, 5747-5755
63. Cortez-Retamozo, V., Lauwereys, M., Hassanzadeh Gh, G., Gobert, M., Conrath, K., Muyldermans, S., De Baetselier, P., and Revets, H. (2002) Efficient tumor targeting by single-domain antibody fragments of camels. Int. J. Cancer 98, 456-462
64. Denis, M., Marcinkiewicz, J., Zaid, A., Gauthier, D., Poirier, S., Lazure, C., Seidah, N. G., and Prat, A. (2012) Gene inactivation of PCSK9 reduces atherosclerosis in mice. Circulation 125, 894-901
65. Guella, I., Asselta, R., Ardissino, D., Merlini, P. A., Peyvandi, F., Kathiresan, S., Mannucci, P. M., Tubaro, M., and Duga, S. (2010) Effects of PCSK9 genetic variants on plasma LDL cholesterol levels and risk of premature myocardial infarction in the Italian population. J. Lipid Res. 51, 3342-3349
66. Huang, Y., Ballinger, D. G., Stokowski, R., Beilharz, E., Robinson, J. G., Liu, S., Robinson, R. D., Henderson, V. W., Rossouw, J. E., and Prentice, R. L. (2012) Exploring the interaction between SNP genotype and postmenopausal hormone therapy effects on stroke risk. Genome Med. 4, 57
67. dos Santos, C., and Marshall, J. C. (2014) Bridging lipid metabolism and innate host defense. Sci. Transl. Med. 6, 258fs41
68. Sun, X., Essalmani R, Day R, Khatib, A. M., Seidah, N. G., and Prat, A. (2012) Proprotein convertase subtilisin/kexin type 9 deficiency reduces melanoma metastasis in liver. Neoplasia 14, 1122-1131
69. Benjannet, S., Saavedra, Y. G., Hamelin, J., Asselin, M. C., Essalmani, R., Pasquato, A., Lemaire, P., Duke, G., Miao, B., Duclos, F., Parker, R., Mayer, G., and Seidah, N. G. (2010) Effects of the prosegment and pH on the activity of PCSK9: evidence for additional processing events. J. Biol. Chem. 285, 40965-40978
70. Hussack, G., Arbabi-Ghahroudi, M., van Faassen, H., Songer, J. G., Ng, K. K., MacKenzie, R., and Tanha, J. (2011) Neutralization of Clostridium difficile toxin A with single-domain antibodies targeting the cell receptor binding domain. J. Biol. Chem. 286, 8961-8976
71. Schippers, I. J., Moshage, H., Roelofsen, H., Müller, M., Heymans, H. S., Ruiters, M., and Kuipers, F. (1997) Immortalized human hepatocytes as a tool for the study of hepatocytic (de-)differentiation. Cell Biol. Toxicol. 13, 375-386
72. Maclean, J., Koekemoer, M., Olivier, A. J., Stewart, D., Hitzeroth, I. I., Rademacher, T., Fischer, R., Williamson, A. L., and Rybicki, E. P. (2007) Optimization of human papillomavirus type 16 (HPV-16) L1 expression in plants: comparison of the suitability of different HPV-16 L1 gene variants and different cell-compartment localization. J. Gen. Virol. 88, 1460-1469
73. Voinnet, O., Rivas, S., Mestre, P., and Baulcombe, D. (2003) An enhanced transient expression system in plants based on suppression of gene silencing by the p19 protein of tomato bushy stunt virus. Plant J. 33, 949-956